Related Experiment Video
Updated: Jun 29, 2025
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
Potential Therapeutic Targets for Hypotension in Duchenne Muscular Dystrophy
Harshi Saxena1, Neal L Weintraub1, Yaoliang Tang1
1Vascular Biology Center, Department of Medicine, Medical College of Georgia at Augusta University, 1460 Laney Walker Blvd, Augusta, GA 30912, USA.
Insights
Duchenne Muscular Dystrophy (DMD) patients may experience low blood pressure due to increased KCNQ5 and RyR2 gene expression in blood vessels. Targeting these channels could offer new hypotension treatments for DMD.
Area of Science:
- Cardiovascular Science
- Genetics
- Pharmacology
Background:
- Duchenne Muscular Dystrophy (DMD) involves DMD gene mutations affecting the cardiovascular system.
- DMD patients are prone to symptomatic hypotension, but underlying mechanisms remain unclear.
Purpose of the Study:
- To investigate the genetic basis of hypotension in Duchenne Muscular Dystrophy.
- To identify potential therapeutic targets for managing hypotension in DMD patients.
Main Methods:
- Analysis of single-cell RNA sequencing data from DMD mutant mice.
- Identification of upregulated genes in vascular smooth muscle cells.
Main Results:
- Potassium voltage-gated channel subfamily Q member 5 (KCNQ5) and ryanodine receptor 2 (RyR2) expression were significantly upregulated in DMD mice.
- These genes are identified as potential candidates contributing to hypotension in DMD.
Conclusions:
- Heightened KCNQ5 and RyR2 expression likely contributes to decreased arterial blood pressure in DMD.
- Pharmacological inhibition of KCNQ5 and RyR2 channels shows promise for managing DMD-associated hypotension.
- This research opens new avenues for improving clinical outcomes in Duchenne Muscular Dystrophy patients.
Abstract:
Duchenne Muscular Dystrophy (DMD) is marked by genetic mutations occurring in the DMD gene, which is widely expressed in the cardiovascular system. In addition to developing cardiomyopathy, patients with DMD have been reported to be susceptible to the development of symptomatic hypotension, although the mechanisms are unclear. Analysis of single-cell RNA sequencing data has identified potassium voltage-gated channel subfamily Q member 5 (KCNQ5) and possibly ryanodine receptor 2 (RyR2) as potential candidate hypotension genes whose expression is significantly upregulated in the vascular smooth muscle cells of DMD mutant mice. We hypothesize that heightened KCNQ5 and RyR2 expression contributes to decreased arterial blood pressure in patients with DMD. Exploring pharmacological approaches to inhibit the KCNQ5 and RyR2 channels holds promise in managing the systemic hypotension observed in individuals with DMD. This avenue of investigation presents new prospects for improving clinical outcomes for these patients.
Related Concept Videos
01:23Antihypertensive Drugs: Vasodilators
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:21Satellite Stem Cells and Muscular Dystrophy
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...